FDA panel urges limits on Sanofi antibiotic
Sat, 16 Dec 2006 01:21 AM EST
... SILVER SPRING, Maryland (Reuters) - Sanofi-Aventis antibiotic Ketek should stay on the market but use should be limited to treating pneumonia, U.S. advisers said on Friday after reviewing rare cases of liver failure and other problems. ...
Related Topics
- Antibiotics
- Liver Panel
- Carcinogens
- Antibiotic Resistance
- Hydrocortisone, Neomycin, and Polymyxin Otic
- Tacrolimus ointment
- Mammography
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Antibiotic-associated diarrhea
- Thalidomide
- Electrolytes
- Polymyxin B, Bacitracin, and Neomycin
- Cefuroxime
- Cephalexin
- Viral Infections
- Sulfamethoxazole and Trimethoprim
- Food Labeling
- Streptomycin
- Drug Safety

Not Signed In -


